TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01462253

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clofarabine, Cyclophosphamide
Description: The proposed treatment schedule consists of a combination of Clofarabine plus Cyclophosphamide administered over 5 consecutive days (Treatment scheme).
Study: NCT03926663

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: patients will receive 0.25% bupivacaine (with an average dose of 1-1.5 mg/kg) preincisional local infiltration of the nasal mucosa.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: patients will receive 0.25% bupivacaine (with an average dose of 1-1.5 mg/kg) preincisional local infiltration of the nasal mucosa.
Study: NCT01042015

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Emergency preservation and resuscitation
Description: This involves the induction of profound hypothermia using a flush of ice-cold saline into the aorta. Once hypothermia is achieved, the subject would undergo rapid operative interventions to control bleeding followed by resuscitation/rewarming with cardiopulmonary bypass.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard resuscitation
Description: Standard resuscitation includes an emergency department thoracotomy, open cardiac massage, and fluid resuscitation.
Study: NCT02065258

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Breathing exercise
Description: It will be based on Yoga´s breathing technique (Eliade, 1996) and will be focus on to stimulate nasal and diaphragmatic breathings, to increase expiratory time, to slow respiratory flow and to regulate the breathing rhythm. Breathing exercises will be divided into 3 phases (lasting one month each) with progressive intensity every 8 sessions.~All participants will be required to maintain their normal medical regimens during the interventions. Will be part of the routine of breathing exercises the following exercises: I) Kapalabhati, II) Uddhiyana

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic exercise
Description: Exercise will be performed on a treadmill (Imbramed Export Plus, Brazil) with the initial intensity of 60% of the maximum predicted heart rate for patient´s age (Tanaka et al, 2001) reaching a maximal of 80% during the training. The intensity values will be calculated using Karvonen's formule (1957). Exercise intensity will be increased if the patient do not present any increase in asthma symptoms during the exercise for 2 consecutive training days. Before and after every session, patients will perform a peak expiratory flow test and if values were lower than 70% of the patient´s maximum value, they will be advised to use the rescue dose of bronchodilator prescribed the their physician
Study: NCT03828019

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Adalimumab (ADA)
Description: Adalimumab is a fully-human monoclonal antibody to TNF-α, which is approved by the U.S. FDA for the treatment of non-infectious intermediate, posterior, and panuveitides in adults and children 2 years of age and older.
Study: NCT02185404

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: wearing the iStride device
Description: The device mimics the actions of the split-belt treadmill, but can be used during over-ground walking and in one's own home, thus enabling long-term training. This device does not require any external power and is completely passive; all necessary forces are redirected from the natural forces present during walking since it utilizes the wearer's weight to generate its movements. This research aims to test the iStride on individuals with stroke in their own home in order to determine if the related effects that we saw in the clinic, can also benefit patients at home.
Study: NCT01505634

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Relebactam 250 mg
Description: Participants randomized to receive relebactam 250 mg will be administered a 250 mg dose of relebactam IV in a blinded fashion once every 6 hours with each dose infused over a 30-minute interval.
Study: NCT03828019

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Conventional immunosuppression (CON)
Description: The study ophthalmologist will select amongst the permissible drugs (methotrexate, mycophenolate mofetil or azathioprine for antimetabolites; cyclosporine or tacrolimus for calcineurin inhibitors) taking into account the side effect profile of each drug with respect to subject's clinical situation.
Study: NCT00882297

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Echoguided vein puncture
Description: Puncture with echographic visualization of vein in transversal and longitudinal way.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Echoguided vein puncture
Description: Puncture with echographic visualization of vein in transversal and longitudinal way.
Study: NCT02707575

Intervention type: DRUG
Intervention: Ranibizumab
Description: Three monthly consecutive injections of 0.5-mg ranibizumab will be performed. Aqueous humor samples will be taken each time an intravitreal injection in indicated and performed.
Study: NCT03703193

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dry Needling
Description: A single session of modulatory interventions combined with a single session of dry needling into the shoulder muscles which active trigger points will reproduce the shoulder pain symptoms.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical Therapy
Description: A single session of modulatory interventions targeting modulation of central nervous system.
Study: NCT01505634

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Relebactam 125 mg
Description: Participants randomized to receive relebactam 125 mg will be administered a 125 mg dose of relebactam IV in a blinded-treatment fashion once every 6 hours with each dose infused over a 30-minute interval.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: imipenem/cilastatin 500 mg
Description: A 500 mg dose of imipenem/cilastatin will be administered IV in an open-label fashion once every 6 hours with each dose infused over a 30-minute interval.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: imipenem/cilastatin 500 mg
Description: A 500 mg dose of imipenem/cilastatin will be administered IV in an open-label fashion once every 6 hours with each dose infused over a 30-minute interval.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: imipenem/cilastatin 500 mg
Description: A 500 mg dose of imipenem/cilastatin will be administered IV in an open-label fashion once every 6 hours with each dose infused over a 30-minute interval.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to relebactam
Description: Participants randomized to receive imipenem/cilastatin alone will receive a placebo-matching infusion of IV normal saline (0.9%) once every 6 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin
Description: After at least 96 hours of IV treatment, participants may be switched, at the discretion of the investigator, to 500 mg ciprofloxacin, administered orally, twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin
Description: After at least 96 hours of IV treatment, participants may be switched, at the discretion of the investigator, to 500 mg ciprofloxacin, administered orally, twice daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ciprofloxacin
Description: After at least 96 hours of IV treatment, participants may be switched, at the discretion of the investigator, to 500 mg ciprofloxacin, administered orally, twice daily
Study: NCT03957564

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy with PSOX regimen.
Description: Resectable gastric or gastro-oesophageal junction cancer patients receiving neoadjuvant chemotherapy with PSOX（Paclitaxel+Oxaliplatin+S1）regimen.~The details are as follows:~Paclitaxel 135mg/m2 d1, Oxaliplatin 85mg/m2 d1, S1 40-60mg/m2 twice daily, d1-14 , 21 days is one cycle.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Detect the imaging data and levels of CTC, ctDNA, cfDNA, CEA, CA19-9, CA72-4 in plasma.
Description: Detect the imaging data and levels of CTC, ctDNA, cfDNA, CEA, CA19-9, CA72-4 in 3 time points：Before neoadjuvant chemotherapy, After 2-3 cycles of neoadjuvant chemotherapy, 10 days after operation.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Detect the tumor related DNA in pathological tissues after operation.
Description: Detect the tumor related DNA in pathological tissues after operation.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Follow-up of DFS and OS in patients with gastric cancer after operation.
Description: Follow-up of DFS and OS in patients with locally advanced or resectable gastric or gastro-oesophageal Junction cancer.
Study: NCT02846532

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Description: Participants will receive oral suspension containing rivaroxaban 1 milligram per milliliter (mg/ml) twice daily in Part A and Part B. Following total daily doses of Rivaroxaban will be administered based on the weight of the participants: 7 to \<8 kilogram (kg) will receive 2.2 milligram (mg); 8 to \<10 kg will receive 3.2 mg; 10 to\<12 kg will receive 3.4 mg; 12 to \<20 will receive 4.0 mg and 20 to \<30 will receive 5.0 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic Acid
Description: Participants will receive 5 milligram per kilogram (mg/kg) of acetylsalicylic acid once daily up to 12 months in Part B.
Study: NCT01512303

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sudarshan Kriya Yoga
Description: SKY incorporates yoga, discussion periods and several types of breathing exercises for relaxation.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Stress Reduction
Description: MBSR incorporates yoga, discussion periods, and several types of meditation, all involving attention to the present moment and acceptance of any feelings, sensations or thoughts
Study: NCT04077996

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Peritonitis treatment placed in APD
Description: Antibiotic treatment of peritontiis placed in bags of Automated peritoneal dialysis.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Peritonitis treatment with one exchange in CAPD
Description: Antibiotic treatment of peritontiis placed in one bag of Continuos ambulatory peritoneal dialysis per 6 hours each day.
Study: NCT05656677

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Passive parental involvement
Description: One parent watching a procedural painful intervention, two nurses executing facilitated tucking

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Active parental involvement
Description: One parent watching a procedural painful intervention and at the same time executing facilitated tucking
Study: NCT04055792

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: Sintilimab 200mg intravenously on day 1 and Anlotinib 12 mg on days 1-14 once every 3 weeks
Study: NCT04105504

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glutathione
Description: Oral glutathione capsule (500 mg), were taken once daily by the subjects.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: Placebo oral capsule were taken once daily by the subjects.
Study: NCT00619073

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: clopidogrel + aspirin
Description: Clopidogrel 75mg plus aspirin 81mg, tablet by mouth daily for 14 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo plus aspirin 81 mg, tablet by mouth daily for 14 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: Aspirin 81mg tablet by mouth continued daily alone for 43 days after day 14.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Aspirin
Description: Aspirin 81mg tablet by mouth continued daily alone for 43 days after day 14.
Study: NCT02180360

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Capoeira training group
Description: Capoeira training: The experimental Capoeira training protocol, based in the modern styles of Capoeira was applied by an instructor with 17 years of experience in teaching Capoeira, followed the directions of the Basic Programmed Lesson, created by Geraldo Pereira d'Santana (Master Santana) in a Capoeira group called IUNA from the city of São Paulo, Brazil.~In order to perform the Basic Programmed Lesson program, the activities were divided in four stages, being composed of the main movement that characterizes Capoeira (the ginga) and by other movements such as: dodging, unbalancing, traumatizing and acrobatic.~An important thing to highlight in the experimental protocol is that the training performed in the present study used only specific movements of Capoeira, without applying any other traditional stretching exercises. Therefore, it is possible to infer that the results obtained are due to the experimental protocol.
Study: NCT02280018

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-49122944, 5 milligram (mg)
Description: Participants will receive single dose of 5 mg JNJ-49122944, administered as a 22.2 mL IV infusion over 45 minutes on Day 1.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive placebo matched to JNJ-49122944, administered as a 22.2 mL IV infusion over 45 minutes on Day 1.
Study: NCT03317938

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fecobionics
Description: Fecobionics is a new device for studying defecation
Study: NCT02526459

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Birth plan
Description: Patient will receive a birth plan
Study: NCT02882633

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 30ml bolus of bupivacaine
Description: Local anesthetic

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 30ml bolus of bupivacaine
Description: Local anesthetic
Study: NCT02745275

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer-led Health Education
Description: Peer-led health education
Study: NCT04116385

Intervention type: DIAGNOSTIC_TEST
Intervention: Quantra System
Description: Diagnostic device to monitor coagulation properties of a whole blood sample at the point-of-care.
Study: NCT04503239

Intervention type: DEVICE
Intervention: G6
Description: Wear 9 wear periods of the 10-day CGM

Intervention type: DEVICE
Intervention: G6
Description: Wear 9 wear periods of the 10-day CGM

Intervention type: DEVICE
Intervention: G6
Description: Wear 9 wear periods of the 10-day CGM

Intervention type: DEVICE
Intervention: G6
Description: Wear 9 wear periods of the 10-day CGM

Intervention type: DEVICE
Intervention: G6
Description: Wear 9 wear periods of the 10-day CGM

Intervention type: DEVICE
Intervention: G6
Description: Wear 9 wear periods of the 10-day CGM

Intervention type: DEVICE
Intervention: G6
Description: Wear 9 wear periods of the 10-day CGM

Intervention type: DEVICE
Intervention: G6
Description: Wear 9 wear periods of the 10-day CGM

Intervention type: DEVICE
Intervention: G6
Description: Wear 9 wear periods of the 10-day CGM
Study: NCT03276000

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: office hysteroscopy
Description: A rigid 30 4-mm hysteroscope (Karl Storz Endoscopy) will be used without anaesthesia or analgesia 3 hours after administration of misoprostol. The uterine cavity will be distended with normal saline solution at a pressure of 100-120 mm Hg. The vaginoscopic ''no touch'' technique was followed; no speculum or tenaculum was used.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: office hysteroscopy
Description: A rigid 30 4-mm hysteroscope (Karl Storz Endoscopy) will be used without anaesthesia or analgesia 3 hours after administration of misoprostol. The uterine cavity will be distended with normal saline solution at a pressure of 100-120 mm Hg. The vaginoscopic ''no touch'' technique was followed; no speculum or tenaculum was used.
Study: NCT00820521

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: active

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT02517164

Intervention type: OTHER
Intervention: Measurement of serum 25-hydroxyvitamin D

Intervention type: OTHER
Intervention: Measurement of serum 25-hydroxyvitamin D

Intervention type: OTHER
Intervention: Analysis of global cognitive efficiency score assessed by the Montreal Cognitive Assessment (MoCA).

Intervention type: OTHER
Intervention: Analysis of global cognitive efficiency score assessed by the Montreal Cognitive Assessment (MoCA).
Study: NCT04687800

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextenza 0.4mg intracanalicular Insert
Description: intracanalicular insert delivery system

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Durezol 0.05% Ophthalmic Emulsion
Description: Standard therapy, topical steroid drop
Study: NCT03263507

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline .9%

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donidalorsen
Description: Donidalorsen administered subcutaneously
Study: NCT01464502

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard CRT Implant

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pressure-wire guided CRT implant
Description: A pressure wire will be sited in the left ventricle to measure dP/dT max. The LV lead position that gives the highest dP/dT max will be the final position used.
Study: NCT04354714

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: For patients unable to swallow pills, a ruxolitinib suspension will be administered through a nasogastric/orogastric tube

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral blood draw
Description: -Screening, Day 2, Day 4, Day 8, Day 15, and Day 29
Study: NCT00549367

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Nutrition Counselling
Description: Clients will receive ongoing nutrition assessment and dietary counselling. The intervention arm will receive all baseline assessments and individual nutritional assessment, counselling and nutrition management plans using standards of practice
Study: NCT00874419

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib
Description: erlotinib 150 mg oral, once a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: gemcitabine/carboplatin
Description: gemcitabine 1000mg/m2 on d1,8 with carboplatin AUC=5 on d1 intravenously, every 3 weeks, up to 4 cycles
Study: NCT02105402

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PROMPT
Description: The PROMPT approach utilizes a motor-speech hierarchy (MSH) to guide speech language pathologists (SLP) in selecting speech movement goals for treatment. PROMPT treatment generally proceeds systematically in a bottom-up fashion starting with the lowest subsystem in the hierarchy where a child has control issues. Furthermore, in the PROMPT approach specific techniques are used to stimulate sensory input that are assumed to facilitate the formation of sensory-motor pathways required for the acquisition and accurate production of speech movement patterns. As the speech motor behaviors are established, the clinician reduces the number of cues and the frequency and immediacy of feedback and practices transfer and generalization activities.
Study: NCT01852994

Intervention type: DRUG
Group type: OTHER
Intervention: Testosterone replacement
Description: Application quarterly of Testosterone Undecylate
Study: NCT00438568

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regular Insulin
Description: administered intra-nasally twice a day for 16 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regular Insulin
Description: administered intra-nasally twice a day for 16 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: administered intra-nasally twice a day for 16 weeks
Study: NCT00329797

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Calcium
Description: A single dose of 500 mg of elemental calcium orally each day for 3 years.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Calcium
Description: A single dose of 500 mg of elemental calcium orally each day for 3 years.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Zoledronic acid
Description: Patients receive IV over 15 minutes once every 6 months for 3 years. The goal dose of zoledronic acid is 4 mg, but the selection of dose is determined based on calculated creatinine clearance at baseline.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: radiation therapy
Description: Patients must receive external beam irradiation, brachytherapy (HDR or LDR), or a combination of external beam irradiation and brachytherapy at the discretion of the treating physician. Dose/duration also will be at the discretion of the treating physician; however, dose will not exceed 45 Gy to 100% of the proximal femur, and no proximal femur will receive ≥ 60 Gy.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Patients must receive external beam irradiation, brachytherapy (HDR or LDR), or a combination of external beam irradiation and brachytherapy at the discretion of the treating physician. Dose/duration also will be at the discretion of the treating physician; however, dose will not exceed 45 Gy to 100% of the proximal femur, and no proximal femur will receive ≥ 60 Gy.
Study: NCT01852994

Intervention type: DRUG
Group type: OTHER
Intervention: Testosterone replacement
Description: Application quarterly of Testosterone Undecylate

Intervention type: OTHER
Group type: OTHER
Intervention: Exercise training
Description: Aerobic and strength exercise training
Study: NCT00329797

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LHRH
Description: LHRH therapy must take place for a minimum of one year. Choice of LHRH agonist, dose, and duration are at the discretion of the treating physician.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LHRH
Description: LHRH therapy must take place for a minimum of one year. Choice of LHRH agonist, dose, and duration are at the discretion of the treating physician.
Study: NCT01852994

Intervention type: OTHER
Group type: OTHER
Intervention: Exercise training
Description: Aerobic and strength exercise training
Study: NCT00329797

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D
Description: 400 IU (10μg), orally each day for 3 years.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: 400 IU (10μg), orally each day for 3 years.
Study: NCT03791099

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metronidazole
Description: After subgingival ultrasonic scaling is performed, metronidazole in polymer matrix is applied to the selected periodontal pockets.